Effects of Whole Body Vibration Training in Patients With Interstitial Lung Disease

NCT03560154 | Unknown

• 1 other identifier: N-85
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Interstitial lung disease (ILD) is a diverse group of parenchymal lung disorders characterized by restrictive lung function and impaired alveolar diffusion capacity, leading to dyspnea on exertion, reduced exercise endurance, and poor quality of life. Patients usually complain of progressive breathlessness, persisting non-productive cough, which occurs with exercise. Hemoptysis, fever, chest pain are also seen. The most common comorbidity in chronic lung diseases is the progressive loss of exercise tolerance. Not only dyspnea, but also peripheral muscle dysfunction and cognitive deficits such as, anxiety and depression are responsible for the reduction of mobility in the patient. In the context of pulmonary rehabilitation (PR) program to be applied in interstitial lung diseases; upper and lower limb endurance, stretching and relaxation techniques, aerobic exercise training, respiratory muscle training, training of energy conservation methods, support by determining oxygen requirement, nutritional evaluation, prevention of weight and muscle loss, psycho-social support. The purpose of PR programs in this disease is; to improve muscle strength, endurance, and mechanical activity, to improve dyspnea sensation, to improve functional capacity, to inform and educate the patient about the patient's disease. The use of whole body vibration (TVT) is an increasingly common method of therapeutic use in order to improve neuromuscular performance. TVT applications have shown that increases muscle activity, muscle strength and muscle strength, improves lower extremity blood circulation and balance, and increases growth hormone production. TVT training effects have rarely been studied in patients with pulmonary disease. Muscle strength and performance enhancement were significant effects of TVT, which was emphasized as a promising exercise method for those with chronic obstructive pulmonary disease (COPD). Over the past decade, endurance and strength training has been established as the most important components of exercise training programs in patients with COPD and ILD. Therefore, inclusion of TVT into exercise training programs in ILD patients may lead to beneficial results. The investigators hypotheses are:

1. 1.the combination of home respiratory exercises with whole body vibration training may lead to more improved respiratory muscle strength, dyspnoea, functional capacity, balance, peripheral muscle strength and quality of life in ILD patients
2. 2.when applied as an isolated intervention, home respiratory exercises programme may lead to lower results than combination programs.

Conditions

Interstitial Lung Disease; Scleroderma; Idiopathic Pulmonary Fibrosis

Keywords

Pulmonary Function Test; Peripheral Muscle strength; Postural balance; Dyspnea; Pulmonary Muscle Strength; Functional Capacity; Fatigue; Quality of Life

Outcome Measures

Primary Outcomes (5)

• Pulmonary Function Test

  The pulmonary function test (PFT) will be performed with a portable spirometry device (Spirobank II) with the nose closed and at least three times in the sitting position. After the nose is tightened with a latch, the person breathes normally on the spirometer. After a few normal inspirations and expirations, it is desirable to take a deep breath at the end of the expiration at the level of rest, and to release the air slowly and continuously afterwards. With this application, the volumes and capacities outside the residual volume (RV), functional residual capacity (FRC) and total lung capacity (TLC) are calculated.

  4 weeks

• Diffusing capacity for carbon monoxide (DLCO)

  The single breath carbon monoxide diffusion test method will be used to calculate the diffusion capacity. Carbonmonoxide Diffusion (DLCO) measurement is an important noninvasive test that provides information on pulmonary gas exchange. The CO concentrations are measured by passing the analyzer through a breathing air analyzer of the patient, which is then exhaled into the device; the amount of CO transferred to the blood is calculated from the difference between the inspired air and the CO concentrations in the expired air.

  4 weeks

• Respiratory muscle strength

  Respiratory muscle strength will be measured using a portable electronic mouth measuring instrument (MicroRPM; Micro Medical, UK). Maximum inspiratory (MIP) and expiratory (MEP) pressures are noninvasive tests that indirectly indicate respiratory muscle strength. It is the intraoral pressure measured during maximal inspiration and maximal respiration against a valve (shutter) that closes the respiratory tract during expiration. The best of three measurements is accepted.

  4 weeks

• 6-minute walk test (6MWT)

  Functional exercise capacity was assessed using the 6-minute walk test (6MWT). Patients will be walked in a 30-meter-long corridor for 6 minutes and the maximum walking distance will be measured. Before and after the test, heart rate, blood pressure and pulse oximeter will measure O2 saturation, and according to Borg scale, dyspnea and fatigue level will be determined. Oxygen will be provided immediately following exercise for patients who desaturate (SpO2 \<88%), or as needed.

  4 weeks

• 6-minute pegboard and ring test (6PBRT)

  Subjects are asked to sit straight in a chair and a pegboard with multiple peg positions is placed in front of the subject at arm's length from the body. Two pegs are positioned at the shoulder level and 2 at 20 cm above the shoulder level, and 10 rings (1/2 oz per ring) are put on each of the 2 lower pegs. The final score is the total number of rings moved during the 6-minute period. Subjects are permitted to stop and rest during the test if they feel severe dyspnea, fatigue, or other discomfort, and continue moving the pegs as soon as they can. Subjects are asked to score the perceived dyspnea and fatigue after the test by the Borg scale. Each subject performe the PBRT twice. A pulse oximeter is used to monitor heart rate (HR) and arterial oxygen saturation (Sao2), and measure blood pressure (BP) before and after each test.

  4 weeks

Secondary Outcomes (6)

• Timed Up and Go Test (TUG)

  4 weeks

• Sit to Stand Test (STS)

  4 weeks

• Static Posturography System (TETRAX)

  4 weeks

• Peripheral Muscle Strength Measurement

  4 weeks

• The Fatigue Severity Scale (FSS)

  4 weeks

Study Arms (2)

Whole Body Vibration Training

EXPERIMENTAL

whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. In TVT training; Eight kinds of exercises will be provided, including 3 sessions per week for 4 weeks. The duration of each session will vary between 8-30 minutes. The frequency, amplitude, and duration of the TVT will be gradually increased from the lowest intensity to the level that the patient can tolerate. 8 exercises will be applied: for lower extremity; high squat, deep squat, right/left lunge, calf raise, for upper extremity; front raise, bent over lateral, biceps curl, and cross over. Before TVT application, 5-8 min. warm-up exercises will be applied. If desaturation (\<88%) develops during the training in the patient, an oxygen mask will be used to ensure adequate oxygenation. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.

Other: Whole Body Vibration Training

Home respiratory exercises

NO INTERVENTION

Respiratory exercises will be taught to the patient. Duration of the respiratory exercises is at least 10 minute per session, 7 days a week for 4 weeks. A weekly phone call will be provided and exercise will be followed.

Interventions

Whole Body Vibration Training OTHER

whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.

Whole Body Vibration Training

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with interstitial lung disease (Idiopathic Pulmonary Fibrosis, pneumoconiosis, chronic hypersensitivity pneumonia, radiation fibrosis, collagenosis pulmonary involvement, nonspecific interstitial pneumonitis-NSIP, idiopathic NSIP)
• Patients whose stability and medical treatment have not been changed for the last 3 months will be included in the study.

You may not qualify if:

• Malignant tumor,
• presence of co-morbidities that prevent exercise training (severe orthopedic or neurological deficit, unstable cardiac disease)
• The knee and / or hip joint replacement operation has been performed,
• having lower and upper limb amputation,
• taking any hormone replacement or medication that may affect the normal metabolism of the musculoskeletal system,
• presence of neurological (MS, intracranial tumor, neurodegenerative diseases, cerebrovascular event, epilepsy) disease which will affect balance and proprioception,
• those with drug use history (antidepressants, anticonvulsants, sedatives, betahistine) that may affect the balance,
• having Ischemic heart disease, dilate, hypertrophic or nonidiopathic cardiomyopathy,
• having pacemaker entity, By-pass, coronary stent,
• having uncontrolled DM,
• presence of acute arthritis / tendinopathy,
• O2 saturation in room air \<80% (resting), patient with advanced respiratory failure,
• having severe neurological and / or metabolic pathologies,
• having hemodynamic instability,
• Being pregnant and breastfeeding,

Sponsors & Collaborators

• Istanbul University: lead

Study Sites (1)

Nur Selin Of

Istanbul, Istanbul University/Cerrahpasa Faculty of Medicine, 34096, Turkey (Türkiye)

Location

Related Publications (25)

• Salhi B, Malfait TJ, Van Maele G, Joos G, van Meerbeeck JP, Derom E. Effects of Whole Body Vibration in Patients With COPD. COPD. 2015;12(5):525-32. doi: 10.3109/15412555.2015.1008693. Epub 2015 Aug 4.

  PMID: 26457458 BACKGROUND

• Turner S, Torode M, Climstein M, Naughton G, Greene D, Baker MK, Fiatarone Singh MA. A randomized controlled trial of whole body vibration exposure on markers of bone turnover in postmenopausal women. J Osteoporos. 2011;2011:710387. doi: 10.4061/2011/710387. Epub 2011 Jun 27.

  PMID: 21772975 BACKGROUND

• Gloeckl R, Jarosch I, Bengsch U, Claus M, Schneeberger T, Andrianopoulos V, Christle JW, Hitzl W, Kenn K. What's the secret behind the benefits of whole-body vibration training in patients with COPD? A randomized, controlled trial. Respir Med. 2017 May;126:17-24. doi: 10.1016/j.rmed.2017.03.014. Epub 2017 Mar 14.

  PMID: 28427544 BACKGROUND

• Gloeckl R, Heinzelmann I, Kenn K. Whole body vibration training in patients with COPD: A systematic review. Chron Respir Dis. 2015 Aug;12(3):212-21. doi: 10.1177/1479972315583049. Epub 2015 Apr 22.

  PMID: 25904085 BACKGROUND

• Cardim AB, Marinho PE, Nascimento JF Jr, Fuzari HK, Dornelas de Andrade A. Does Whole-Body Vibration Improve the Functional Exercise Capacity of Subjects With COPD? A Meta-Analysis. Respir Care. 2016 Nov;61(11):1552-1559. doi: 10.4187/respcare.04763. Epub 2016 Sep 20.

  PMID: 27651524 BACKGROUND

• Polatli M, Yorgancioglu A, Aydemir O, Yilmaz Demirci N, Kirkil G, Atis Nayci S, Kokturk N, Uysal A, Akdemir SE, Ozgur ES, Gunakan G. [Validity and reliability of Turkish version of St. George's respiratory questionnaire]. Tuberk Toraks. 2013;61(2):81-7. doi: 10.5578/tt.5404. Turkish.

  PMID: 23875584 BACKGROUND

• Deniz S, Sahin H, Yalniz E. Does the severity of interstitial lung disease affect the gains from pulmonary rehabilitation? Clin Respir J. 2018 Jun;12(6):2141-2150. doi: 10.1111/crj.12785. Epub 2018 Mar 24.

  PMID: 29498799 BACKGROUND

• Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014 Oct 6;(10):CD006322. doi: 10.1002/14651858.CD006322.pub3.

  PMID: 25284270 BACKGROUND

• Hanada M, Sakamoto N, Ishimatsu Y, Kakugawa T, Obase Y, Kozu R, Senjyu H, Izumikawa K, Mukae H, Kohno S. Effect of long-term treatment with corticosteroids on skeletal muscle strength, functional exercise capacity and health status in patients with interstitial lung disease. Respirology. 2016 Aug;21(6):1088-93. doi: 10.1111/resp.12807. Epub 2016 May 13.

  PMID: 27173103 BACKGROUND

• Schaeffer MR, Ryerson CJ, Ramsook AH, Molgat-Seon Y, Wilkie SS, Dhillon SS, Mitchell RA, Sheel AW, Khalil N, Camp PG, Guenette JA. Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. Eur Respir J. 2018 Jan 18;51(1):1701726. doi: 10.1183/13993003.01726-2017. Print 2018 Jan.

  PMID: 29348183 BACKGROUND

• Nishiyama O, Yamazaki R, Sano H, Iwanaga T, Higashimoto Y, Kume H, Tohda Y. Physical activity in daily life in patients with idiopathic pulmonary fibrosis. Respir Investig. 2018 Jan;56(1):57-63. doi: 10.1016/j.resinv.2017.09.004. Epub 2017 Oct 23.

  PMID: 29325683 BACKGROUND

• Yilmaz Yelvar GD, Cirak Y, Dalkilinc M, Demir YP, Baltaci G, Komurcu M. Impairments of postural stability, core endurance, fall index and functional mobility skills in patients with patello femoral pain syndrome. J Back Musculoskelet Rehabil. 2017;30(1):163-170. doi: 10.3233/BMR-160729.

  PMID: 27392843 BACKGROUND

• Akkaya N, Doganlar N, Celik E, Aysse SE, Akkaya S, Gungor HR, Sahin F. TEST-RETEST RELIABILITY OF TETRAX(R) STATIC POSTUROGRAPHY SYSTEM IN YOUNG ADULTS WITH LOW PHYSICAL ACTIVITY LEVEL. Int J Sports Phys Ther. 2015 Nov;10(6):893-900.

  PMID: 26618068 BACKGROUND

• Wickerson L, Mathur S, Helm D, Singer L, Brooks D. Physical activity profile of lung transplant candidates with interstitial lung disease. J Cardiopulm Rehabil Prev. 2013 Mar-Apr;33(2):106-12. doi: 10.1097/HCR.0b013e3182839293.

  PMID: 23403914 BACKGROUND

• Dale MT, McKeough ZJ, Munoz PA, Corte P, Bye PT, Alison JA. Physical activity in people with asbestos related pleural disease and dust-related interstitial lung disease: An observational study. Chron Respir Dis. 2015 Nov;12(4):291-8. doi: 10.1177/1479972315587518. Epub 2015 Jun 5.

  PMID: 26048393 BACKGROUND

• Dale MT, McKeough ZJ, Troosters T, Bye P, Alison JA. Exercise training to improve exercise capacity and quality of life in people with non-malignant dust-related respiratory diseases. Cochrane Database Syst Rev. 2015 Nov 5;2015(11):CD009385. doi: 10.1002/14651858.CD009385.pub2.

  PMID: 26544672 BACKGROUND

• Dowman L, McDonald CF, Hill C, Lee A, Barker K, Boote C, Glaspole I, Goh N, Southcott A, Burge A, Ndongo R, Martin A, Holland AE. The benefits of exercise training in interstitial lung disease: protocol for a multicentre randomised controlled trial. BMC Pulm Med. 2013 Feb 1;13:8. doi: 10.1186/1471-2466-13-8.

  PMID: 23369075 BACKGROUND

• Tonelli R, Cocconcelli E, Lanini B, Romagnoli I, Florini F, Castaniere I, Andrisani D, Cerri S, Luppi F, Fantini R, Marchioni A, Beghe B, Gigliotti F, Clini EM. Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study. BMC Pulm Med. 2017 Oct 10;17(1):130. doi: 10.1186/s12890-017-0476-5.

  PMID: 29017478 BACKGROUND

• Janaudis-Ferreira T. Exercise training improves exercise capacity and quality of life in people with interstitial lung disease [synopsis]. J Physiother. 2017 Oct;63(4):257. doi: 10.1016/j.jphys.2017.07.002. Epub 2017 Sep 6. No abstract available.

  PMID: 28888691 BACKGROUND

• Wickerson L. Exercise training improves exercise capacity and quality of life in people with interstitial lung disease [commentary]. J Physiother. 2017 Oct;63(4):257. doi: 10.1016/j.jphys.2017.07.001. Epub 2017 Sep 6. No abstract available.

  PMID: 28888689 BACKGROUND

• Keyser RE, Christensen EJ, Chin LM, Woolstenhulme JG, Drinkard B, Quinn A, Connors G, Weir NA, Nathan SD, Chan LE. Changes in fatigability following intense aerobic exercise training in patients with interstitial lung disease. Respir Med. 2015 Apr;109(4):517-25. doi: 10.1016/j.rmed.2015.01.021. Epub 2015 Feb 7.

  PMID: 25698651 BACKGROUND

• Caron M, Hoa S, Hudson M, Schwartzman K, Steele R. Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. Eur Respir Rev. 2018 May 15;27(148):170102. doi: 10.1183/16000617.0102-2017. Print 2018 Jun 30.

  PMID: 29769294 BACKGROUND

• Szentes BL, Kreuter M, Bahmer T, Birring SS, Claussen M, Waelscher J, Leidl R, Schwarzkopf L. Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respir Res. 2018 May 25;19(1):101. doi: 10.1186/s12931-018-0808-x.

  PMID: 29801506 BACKGROUND

• Ramadurai D, Riordan M, Graney B, Churney T, Olson AL, Swigris JJ. The impact of carrying supplemental oxygen on exercise capacity and dyspnea in patients with interstitial lung disease. Respir Med. 2018 May;138:32-37. doi: 10.1016/j.rmed.2018.03.025. Epub 2018 Mar 26.

  PMID: 29724390 BACKGROUND

• Suzuki A, Kondoh Y, Swigris JJ, Ando M, Kimura T, Kataoka K, Yamano Y, Furukawa T, Numata M, Sakamoto K, Hasegawa Y. Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease. Respirology. 2018 Mar 25. doi: 10.1111/resp.13293. Online ahead of print.

  PMID: 29575410 BACKGROUND

MeSH Terms

Conditions

Lung Diseases, Interstitial; Scleroderma, Diffuse; Idiopathic Pulmonary Fibrosis; Dyspnea; Fatigue

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Scleroderma, Systemic; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases; Pulmonary Fibrosis; Respiration Disorders; Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Zerrin Yiğit, Prof

  Istanbul University/Institute of Cardiology

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 6, 2018
• First Posted: June 18, 2018
• Study Start: January 1, 2017
• Primary Completion: September 1, 2020
• Study Completion: September 1, 2020
• Last Updated: July 30, 2020

Record last verified: 2020-07

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)